ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis
NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD
ADMA gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. ADMA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ADMA is growing strongly while it is still valued neutral. This is a good combination! With these ratings, ADMA could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
ADMA had positive earnings in the past year.
In the past year ADMA had a positive cash flow from operations.
In the past 5 years ADMA reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
1.2 Ratios
ADMA has a better Return On Assets (40.50%) than 99.10% of its industry peers.
Looking at the Return On Equity, with a value of 55.37%, ADMA belongs to the top of the industry, outperforming 98.74% of the companies in the same industry.
ADMA has a better Return On Invested Capital (26.28%) than 98.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 40.5% | ||
| ROE | 55.37% | ||
| ROIC | 26.28% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ADMA (45.01%) is better than 98.92% of its industry peers.
ADMA's Operating Margin of 33.10% is amongst the best of the industry. ADMA outperforms 97.84% of its industry peers.
ADMA's Gross Margin of 52.58% is fine compared to the rest of the industry. ADMA outperforms 77.30% of its industry peers.
ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.1% | ||
| PM (TTM) | 45.01% | ||
| GM | 52.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
Compared to 1 year ago, ADMA has more shares outstanding
The number of shares outstanding for ADMA has been increased compared to 5 years ago.
ADMA has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 20.90 indicates that ADMA is not in any danger for bankruptcy at the moment.
ADMA has a better Altman-Z score (20.90) than 93.33% of its industry peers.
ADMA has a debt to FCF ratio of 0.80. This is a very positive value and a sign of high solvency as it would only need 0.80 years to pay back of all of its debts.
The Debt to FCF ratio of ADMA (0.80) is better than 95.50% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that ADMA is not too dependend on debt financing.
ADMA has a worse Debt to Equity ratio (0.19) than 69.55% of its industry peers.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 0.8 | ||
| Altman-Z | 20.9 |
ROIC/WACC2.71
WACC9.7%
2.3 Liquidity
ADMA has a Current Ratio of 6.58. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.58, ADMA is in the better half of the industry, outperforming 64.14% of the companies in the same industry.
ADMA has a Quick Ratio of 3.36. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA has a Quick ratio (3.36) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.58 | ||
| Quick Ratio | 3.36 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 2750.00% over the past year.
The Revenue has grown by 62.23% in the past year. This is a very strong growth!
The Revenue has been growing by 70.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)2750%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)62.23%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%40.22%
3.2 Future
ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.77% yearly.
ADMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.03% yearly.
EPS Next Y35.66%
EPS Next 2Y41.63%
EPS Next 3Y40.4%
EPS Next 5Y33.77%
Revenue Next Year22.05%
Revenue Next 2Y24.83%
Revenue Next 3Y25.8%
Revenue Next 5Y21.03%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 34.49, the valuation of ADMA can be described as expensive.
93.69% of the companies in the same industry are more expensive than ADMA, based on the Price/Earnings ratio.
ADMA's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.45.
Based on the Price/Forward Earnings ratio of 18.23, the valuation of ADMA can be described as rather expensive.
Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 93.51% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ADMA to the average of the S&P500 Index (21.90), we can say ADMA is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.49 | ||
| Fwd PE | 18.23 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.51% of the companies listed in the same industry.
92.79% of the companies in the same industry are more expensive than ADMA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 48.34 | ||
| EV/EBITDA | 27.29 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADMA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 40.40% in the coming years.
PEG (NY)0.97
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y40.4%
5. Dividend
5.1 Amount
ADMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
18.28
+0.14 (+0.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners86.66%
Inst Owner Change2.69%
Ins Owners2.37%
Ins Owner Change1.99%
Market Cap4.36B
Analysts82
Price Target30.08 (64.55%)
Short Float %6.03%
Short Ratio3.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.83%
Min EPS beat(2)-31.17%
Max EPS beat(2)-8.5%
EPS beat(4)2
Avg EPS beat(4)8.19%
Min EPS beat(4)-31.17%
Max EPS beat(4)59.31%
EPS beat(8)4
Avg EPS beat(8)-15.66%
EPS beat(12)7
Avg EPS beat(12)-6.3%
EPS beat(16)10
Avg EPS beat(16)-4.09%
Revenue beat(2)1
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)2.16%
Revenue beat(4)3
Avg Revenue beat(4)7.87%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)21.61%
Revenue beat(8)7
Avg Revenue beat(8)6.02%
Revenue beat(12)11
Avg Revenue beat(12)6.72%
Revenue beat(16)15
Avg Revenue beat(16)7.22%
PT rev (1m)14.57%
PT rev (3m)16.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.69%
EPS NY rev (1m)0.76%
EPS NY rev (3m)-6.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)3.26%
Revenue NY rev (3m)6.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.49 | ||
| Fwd PE | 18.23 | ||
| P/S | 9.5 | ||
| P/FCF | 48.34 | ||
| P/OCF | 43.12 | ||
| P/B | 11.69 | ||
| P/tB | 11.81 | ||
| EV/EBITDA | 27.29 |
EPS(TTM)0.53
EY2.9%
EPS(NY)1
Fwd EY5.49%
FCF(TTM)0.38
FCFY2.07%
OCF(TTM)0.42
OCFY2.32%
SpS1.92
BVpS1.56
TBVpS1.55
PEG (NY)0.97
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 40.5% | ||
| ROE | 55.37% | ||
| ROCE | 33.26% | ||
| ROIC | 26.28% | ||
| ROICexc | 31.16% | ||
| ROICexgc | 31.49% | ||
| OM | 33.1% | ||
| PM (TTM) | 45.01% | ||
| GM | 52.58% | ||
| FCFM | 19.65% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 0.8 | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 138.39% | ||
| Cap/Sales | 2.38% | ||
| Interest Coverage | 11.85 | ||
| Cash Conversion | 63.28% | ||
| Profit Quality | 43.66% | ||
| Current Ratio | 6.58 | ||
| Quick Ratio | 3.36 | ||
| Altman-Z | 20.9 |
F-Score7
WACC9.7%
ROIC/WACC2.71
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2750%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y35.66%
EPS Next 2Y41.63%
EPS Next 3Y40.4%
EPS Next 5Y33.77%
Revenue 1Y (TTM)62.23%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%40.22%
Revenue Next Year22.05%
Revenue Next 2Y24.83%
Revenue Next 3Y25.8%
Revenue Next 5Y21.03%
EBIT growth 1Y243.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.1%
EBIT Next 3Y43.62%
EBIT Next 5Y38.62%
FCF growth 1Y247.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y309.9%
OCF growth 3YN/A
OCF growth 5YN/A